BIOHARVEST SCIENCES INC.

BioHarvest Sciences Inc. announced its Board of Directors has authorized a normal course issuer bid (NCIB) to repurchase up to 5% of its outstanding common shares, not exceeding 1,133,392 shares. The company believes its current market valuation does not fully reflect its underlying value and growth prospects, viewing the share repurchase as an advantageous allocation of capital. CEO Dr. Zaki Rakib stated the company has transformed into a technology-driven entity with a proprietary Botanical Synthesis platform, capable of developing multiple high-value molecules beyond its VINIA business, and believes the market has yet to recognize this transformation. Purchases will be made on the Nasdaq at prevailing market prices and all repurchased shares will be retired.

BioHarvest Sciences Inc. reported Q2 2026 financial results, with revenue increasing 3.8% year-over-year to $8.8 million. The company secured its first CDMO manufacturing agreement for a 20-ton rare botanical fragrance production program, expected to drive profitable growth. Despite a net loss of $3.7 million, BioHarvest revised its full-year guidance, tightening CDMO revenue expectations while reducing its EBITDA loss, and adjusting VINIA D2C revenue downwards to prioritize profitability and manufacturing capacity.

BioHarvest Sciences Inc. reported its unaudited interim condensed consolidated financial statements for the three and six months ended June 30, 2026. The company disclosed factors raising substantial doubt about its ability to continue as a going concern, citing a history of operating losses and increased cash burn. For the six months ended June 30, 2026, revenues increased to $17.34 million, but the net loss remained significant at $6.36 million, and cash and cash equivalents decreased to $15.21 million. The company also noted its operations in Israel and the ongoing monitoring of the regional security situation.

BioHarvest Sciences Inc. announced its participation in Canaccord Genuity's 46th Annual Growth Conference, scheduled for August 11-12, 2026. CEO Zaki Rakib will deliver a company presentation on August 12, 2026, at 1:00 p.m. ET, both in-person in Boston and via a publicly accessible online webcast. The conference provides an opportunity for institutional investors to engage with growth companies, and investors can request one-on-one meetings with BioHarvest Sciences.

BioHarvest Sciences Inc. announced that it will report its second quarter 2026 financial results before the market opens on Tuesday, August 11, 2026. The company will host a conference call and webcast at 8:00 AM Eastern Time to discuss the results and provide a business operations update. CEO Zaki Rakib will present the results and offer insights into the 2026 strategy and growth plan.

BioHarvest Sciences Inc. announced it received a 4.33 million NIS (approximately $1.4 million USD) non-dilutive grant from the Israel Innovation Authority (IIA). This funding will accelerate the company's plant cell culture programs by integrating advanced data science, machine learning, and AI into its biological development workflows. This marks the second grant from the IIA this year, strengthening BioHarvest's financial position and transforming its early-stage R&D pipeline.

BioHarvest Sciences Inc. announced it will present at the 2026 BIO International Convention in San Diego, California, from June 22-25. The company will showcase its proprietary Botanical Synthesis™ platform on June 24, aiming to engage with pharmaceutical and life science organizations. This presentation seeks to advance discussions with prospective partners for drug discovery, active pharmaceutical ingredients, and next-generation therapeutics, fostering long-term growth and shareholder value.

BioHarvest Sciences reported an 8% year-over-year increase in Q1 2026 revenue to $8.5 million, with gross margins improving to 59%. The company's CDMO business saw significant growth, with revenue up 135% YoY, driven by successful milestones in fragrance and saffron projects, securing over $2 million in new Stage 2 contracts. The VINIA brand's customer base grew to 90,000 active users, and the new Blood Flow Hydration product generated $920,000 in cumulative revenue. The company maintains its annual revenue guidance of $42-$48 million.

BioHarvest Sciences Inc. reported a net loss of $2.64 million for Q1 2026, an increase from $2.34 million in Q1 2025, despite a rise in revenues to $8.51 million from $7.86 million year-over-year. The company continues to face operating losses and has not achieved sustained cash-flow profitability, leading to a "going concern" warning. Operations in Israel are ongoing amidst regional hostilities, though no material adverse impact has been reported.

BioHarvest Sciences Inc. has appointed Nedira Salzman-Frenkel as Vice President of Business Development for its CDMO division. Her role will focus on securing new contracts across pharmaceutical, nutraceutical, nutrition, and cosmetic sectors, aligning with the company's strategy to build long-term customer partnerships. Ms. Salzman-Frenkel brings over a decade of experience in the life sciences industry, including securing significant contracts and leading licensing deals. She will work to achieve revenue targets and support the launch of a new facility next year.